» Articles » PMID: 39066595

Investigation of As A Suitable Diagnostic and Prognostic Biomarker in Various Common Cancer Types: Bioinformatics and Practical Analysis

Overview
Journal Cell J
Specialty Cell Biology
Date 2024 Jul 27
PMID 39066595
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The objective of this study was to assess whether Spen paralogue and orthologue C-terminal domain containing 1 () gene expression could serve as a valuable prognostic and diagnostic biomarker in common cancers, drawing from insights in recent literature. We sought to verify this concept by utilizing data sourced from The Cancer Genome Atlas (TCGA) alongside clinical samples.

Materials And Methods: In this bioinformatics and experimental study, RNA-seq data from 12 common cancers were collected from TCGA Pan-Cancer Atlas using the R package "TCGA BIOLINKS" and normalized for analysis. Various analytical tools, including receiver operating characteristic (ROC) curves, Kaplan-Meier and Coxregression analyses, and pathway enrichment analysis via the molecular signatures database (MSigDB), were applied. Drug resistance/sensitivity correlations with expression were explored using the Gene Expression Omnibus (GEO) database. Clinical colorectal cancer (CRC) samples, including both colon and rectal malignant samples, were also evaluated.

Results: The results showed elevated expression in most cancers (9/12), with notable prognostic value in COAD, HNSC, KICH, and LIHC, and a correlation with poor prognosis in COAD for disease-free survival. ROC curve analysis suggested SPOCD1 as a diagnostic biomarker in the majority of cases (7/12), although this pattern was inconsistent in clinical CRC samples. Pathway enrichment analysis revealed a strong correlation between expression and critical molecular pathways. Unlike former results, we found that SPOCD1 upregulated when interacting with PD-0325901. However, treating with Panobinostat led to downregulation. Both are as anticancer reagents.

Conclusion: This study confirms the potential of as a diagnostic and prognostic biomarker in prevalent cancers. However, extensive clinical data, particularly for CRC, are required to validate its reliability. Different COAD subtypes may exhibit varying correlations with expression levels, underscoring the need for further investigation to fully understand its diagnostic and prognostic value.

Citing Articles

Enhances Cancer Cell Activities and Serves as a Prognosticator in Esophageal Squamous Cell Carcinoma.

Bayasgalan T, Kanda M, Sato Y, Zhu H, Hamrah M, Martinez F Cancer Genomics Proteomics. 2025; 22(2):306-325.

PMID: 39993802 PMC: 11880929. DOI: 10.21873/cgp.20503.